Trial Profile
A Phase I Study to Determine Safety, Tolerability and Preliminary Anti-Staphylococcal Activity of Intranasally Administered XF-73.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2010
Price :
$35
*
At a glance
- Drugs Exeporfinium chloride (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; Therapeutic Use
- 15 Sep 2010 Results were reported at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 15 Sep 2010 New trial record